# Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

Source: https://onco.cc/trials/nct03386513/  
OnCo record `nct03386513` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pivekimab sunirine in blastic plasmacytoid dendritic cell neoplasm and myeloproliferative neoplasms, run by AbbVie, active and no longer recruiting.

## Summary

Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN is a phase 1/2 interventional study registered as NCT03386513 by AbbVie, with 179 participants enrolled, started 2018-01-02 and due to reach its primary completion in 2024-10-02. Interventions recorded: IMGN632. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03386513
- Phase: 1/2
- Setting: A Phase 1/2, Multi-center, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients With CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies
- Sponsor: AbbVie
- Enrolled: 179

## Sources

- ClinicalTrials.gov NCT03386513: https://clinicaltrials.gov/study/NCT03386513

## Connected records

- cancers: [Blastic plasmacytoid dendritic cell neoplasm (BPDCN)](https://onco.cc/cancers/bpdcn/), [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/)
- drugs: [Pivekimab sunirine](https://onco.cc/drugs/pivekimab-sunirine/)
- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/)

---
JSON: https://onco.cc/api/v1/entities/nct03386513.json